Comparative Analysis of Anticoagulation Stability in Critically Ill Patients Receiving Argatroban for Suspected or Confirmed Heparin-Induced Thrombocytopenia Compared with Unfractionated Heparin: A Retrospective Cohort Study
Hematology Reports · 30.04.2026 · 18 (3) · 31
DOI: 10.3390/hematolrep18030031 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Hematology Reports, online erschienen am 30.04.2026. Verfasst von Imran Khan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Montfort Hospital, Ottawa, ON K1K 0T2, Canada. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Montfort Hospital.
Abstract (Originalsprache)
Background
Achieving and maintaining therapeutic anticoagulation with unfractionated heparin in critically ill patients is challenging due to biologic variability, heparin resistance, and limitations of activated partial thromboplastin time (aPTT) monitoring. Argatroban, a direct thrombin inhibitor, provides antithrombin-independent anticoagulation with more predictable pharmacokinetics, but real-world data describing its anticoagulation stability in the intensive care unit (ICU) remain limited.
Objective
This study aimed to compare anticoagulation stability between continuous intravenous argatroban and unfractionated heparin in critically ill patients using time in therapeutic range (TTR) based on aPTT as the primary performance metric.
Methods
A retrospective cohort study was conducted in the ICU and step-down unit of Hôpital Montfort (Ottawa, ON, Canada) between January 2016 and December 2024. Adult patients receiving continuous intravenous argatroban or unfractionated heparin for systemic anticoagulation were included. All aPTT values obtained during active infusion were extracted, and TTR was calculated using linear interpolation between consecutive measurements. Continuous variables were summarized as medians with interquartile ranges and compared using the Wilcoxon rank-sum test; categorical TTR strata were compared using Fisher’s exact test.
Results
Sixty-eight patients met the inclusion criteria, contributing 9 argatroban and 61 heparin infusion courses. Argatroban demonstrated a higher median TTR than heparin (83.3% [IQR 82.0–90.7] vs. 47.5% [32.9–62.4]; p < 0.001), with a moderate-to-large effect size (r = 0.51). Median aPTT values were similar between groups, but argatroban showed narrower dispersion and fewer prolonged subtherapeutic periods. A majority of heparin courses (56.5%) spent
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Montfort Hospital, Ottawa, ON K1K 0T2, Canada.
ORCID-Profile: Imran Khan, Andy Pan, Christine Landry, Kaouther Derouiche, Pierre Thabet
Förderung
- Montfort Hospital
Zitieren
APA
Khan, I., Lamarche, E., Kovacs, B., Hendin, A., Pan, A., Richler, C., Landry, C., Morin, S., Derouiche, K., & Thabet, P. (2026). Comparative Analysis of Anticoagulation Stability in Critically Ill Patients Receiving Argatroban for Suspected or Confirmed Heparin-Induced Thrombocytopenia Compared with Unfractionated Heparin: A Retrospective Cohort Study. Hematology Reports, 18(3), 31. https://doi.org/10.3390/hematolrep18030031
Vancouver
Khan I, Lamarche E, Kovacs B, Hendin A, Pan A, Richler C, et al. Comparative Analysis of Anticoagulation Stability in Critically Ill Patients Receiving Argatroban for Suspected or Confirmed Heparin-Induced Thrombocytopenia Compared with Unfractionated Heparin: A Retrospective Cohort Study. Hematology Reports. 2026;18(3):31. doi:10.3390/hematolrep18030031
BibTeX
@article{Khan2026,
author = {Khan, Imran and Lamarche, Elizabeth and Kovacs, Bernadett and Hendin, Ariel and Pan, Andy and Richler, Caitlin and Landry, Christine and Morin, Sydney and Derouiche, Kaouther and Thabet, Pierre},
title = {Comparative Analysis of Anticoagulation Stability in Critically Ill Patients Receiving Argatroban for Suspected or Confirmed Heparin-Induced Thrombocytopenia Compared with Unfractionated Heparin: A Retrospective Cohort Study},
journal = {Hematology Reports},
year = {2026},
volume = {18},
number = {3},
pages = {31},
doi = {10.3390/hematolrep18030031}
}
EUVIMED